Medigene Yönetim

Yönetim kriter kontrolleri 1/4

Medigene's CEO'su Selwyn Ho, Jul2022 tarihinde atandı, in görev süresi 2.25 yıldır. şirketin hisselerinin 0.42% doğrudan sahiptir ve bu hisselerin değeri CHF 123.15K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.9 yıl ve 7.2 yıldır.

Anahtar bilgiler

Selwyn Ho

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	7.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Selwyn Ho'un ücretlendirmesi Medigene'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€16m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	n/a	n/a	-€16m
Sep 30 2023	n/a	n/a	-€23m
Jun 30 2023	n/a	n/a	-€29m
Mar 31 2023	n/a	n/a	-€19m
Dec 31 2022	€612k	€157k	-€8m

Tazminat ve Piyasa: Selwyn şirketinin toplam tazminatının Swiss pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Selwyn şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Selwyn Ho (53 yo)

2.3yrs

Görev süresi

€612,472

Tazminat

Dr. Selwyn Ho, MBBS, serves as Chief Executive Officer & Chairman of the Executive Management Board at Medigene AG since July 25, 2022. He served as Chief Business Officer at Connect Biopharma Holdings Lim...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Selwyn Ho	CEO & Chairman of Executive Management Board	2.3yrs	€612.47k	0.42% CHF 122.0k
Dolores Schendel	Chief Scientific Officer	10.4yrs	€624.00k	Veri yok
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	no data	€20.00k	Veri yok
Birger Kohlert	Chief Financial Officer	no data	Veri yok	Veri yok
Pamela Keck	Vice President of Investor Relations & Corporate Communications	1.6yrs	Veri yok	Veri yok
Kirsty Crame	VP and Head of Clinical Research & Development	1.6yrs	Veri yok	Veri yok

1.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: MDG1 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	7.2yrs	€20.00k	Veri yok
Anthony Man	Independent Member of the Supervisory Board	3.8yrs	€21.00k	Veri yok
Antoinette Hiebeler-Hasner	Independent Deputy Chairwomen of the Supervisory Board	8.2yrs	€36.00k	Veri yok
Gerd Zettlmeissl	Independent Chairman of the Supervisory Board	7.4yrs	€46.00k	Veri yok
Ronald Scott	Independent Member of the Supervisory Board	7.4yrs	€24.00k	Veri yok
Frank Mathias	Independent Member of the Supervisory Board	6.4yrs	€30.00k	0.071% CHF 20.7k
Peter Krammer	Member of Scientific Advisory Board	7.2yrs	Veri yok	Veri yok
Lawrence Samelson	Member of Scientific Advisory Board	7.2yrs	Veri yok	Veri yok
Micha Drukker	Member of Scientific Advisory Board	7.2yrs	Veri yok	Veri yok
Freda Stevenson	Member of Scientific Advisory Board	7.2yrs	Veri yok	Veri yok
Jolanda de Vries	Member of Scientific Advisory Board	7.2yrs	Veri yok	Veri yok

7.2yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MDG1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.2 yıldır).

Medigene Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Executive Changes

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Recent updates

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings released: €0.66 loss per share (vs €0.34 loss in FY 2022)

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Forecast to breakeven in 2022

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Forecast to breakeven in 2022

Medigene Confirms Revenue Guidance for 2021

No longer forecast to breakeven

Medigene AG Provides Earnings Guidance for the Year 2021

Advisor has left the company

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

Earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş